Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 19 Myeloid 15 Lymphoid 2 Breast 1

Conditions

HER2+ Metastatic Breast Cancer 1

Interventions

Fulvestrant 81 Letrozole 74 Paclitaxel 71 pembrolizumab 67 Specimen Handling 63 Trastuzumab 60 Carboplatin 55 Magnetic Resonance Spectroscopy 50 ribociclib 47 Capecitabine 47 Anastrozole 45 palbociclib 44 pertuzumab 43 Tamoxifen 38 Cyclophosphamide 38 exemestane 37 abemaciclib 37 Biopsy 35 trastuzumab deruxtecan 30 Docetaxel 28 Taxes 27 Gemcitabine 25 Radiotherapy 24 Surveys and Questionnaires 23 130-nm albumin-bound paclitaxel 23 Standard of Care 21 Blood Specimen Collection 21 sacituzumab govitecan 20 olaparib 20 eribulin 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

asciminib × Breast × 90 days × Clear all

NCT07136428 2026-05-06

ASCENdANT

Duke University

Phase 1/2 Not yet recruiting

HER2+ Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡